<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02974946</url>
  </required_header>
  <id_info>
    <org_study_id>2016CAR88</org_study_id>
    <nct_id>NCT02974946</nct_id>
  </id_info>
  <brief_title>Kidney Protection Using the RenalGuard® System in Cardiac Surgery</brief_title>
  <acronym>KIDNEY</acronym>
  <official_title>Kidney Protection Using the RenalGuard® System in Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Royal Wolverhampton Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Royal Wolverhampton Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomised control trial 1:1 in patients at risk of developing Acute&#xD;
      Kidney Injury after cardiac surgery comparing the RenalGuard® System to current medical&#xD;
      treatment. 110 patients will be recruited for each group. The aim of the study is to assess&#xD;
      whether the RenalGuard® system reduces Acute Kidney Injury (AKI) after cardiac surgery as&#xD;
      compared to current practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing elective or in-house urgent cardiac surgery will be approached for the&#xD;
      KIDNEY study if they fulfil the inclusion criteria. Upon consent pre-operative blood tests&#xD;
      will be as per the usual practice. Moreover, 2ml of the serum will be stored for NGAL&#xD;
      analysis.&#xD;
&#xD;
      Following the consenting process, patients will be randomised (envelop- based) into either&#xD;
      having the RenalGuard® System (Study group) or current medical management (Control group).&#xD;
&#xD;
      Study group:&#xD;
&#xD;
      Patients in the study group will have the RenalGuard® System started in anaesthetic room once&#xD;
      the peripheral line and arterial lines are sited. The RenalGuard® System will continue to run&#xD;
      throughout the cardiac procedure in the operating room and up to 6 hours post-op after the&#xD;
      patient has been transferred to the unit. Patients will be managed at a zero balance i.e.&#xD;
      volume of the urine output will be matched to the volume of Hartmann's fluid infusion. Forced&#xD;
      diuresis is then initiated.&#xD;
&#xD;
      Control group:&#xD;
&#xD;
      Patients in the control group will be managed as per current medical practice which will&#xD;
      include no forced diuresis in operating room and the use of inotropes for maintenance of mean&#xD;
      arterial pressure and intravenous furosemide for diuresis.&#xD;
&#xD;
      An additional blood test (NGAL) at six hours post-op will be taken and would require 2mls of&#xD;
      blood. The NGAL specimens will be dealt with by the biochemistry lab (centrifuged &amp; stored)&#xD;
      so that the specimens can be analysed in batches.&#xD;
&#xD;
      Patients kidney function (U&amp;Es) will be tested at the time of post-operatively as per usual&#xD;
      practice (Day1, pre-discharge and as clinically indicated) and at the post-operative surgical&#xD;
      out-patient visit.&#xD;
&#xD;
      Pre-operative, intra-operative and post-operative data will be collected for each patient&#xD;
      group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">September 22, 2019</completion_date>
  <primary_completion_date type="Actual">June 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of AKI as defined by the RIFLE criteria</measure>
    <time_frame>50% rise in pre-op serum creatinine within 3 days of surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Acute Renal Injury</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive the RenalGuard system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard practice will be performed with no RenalGuard system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RenalGuard</intervention_name>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients undergoing surgery (elective or in-house urgent)&#xD;
&#xD;
          2. Patient 18 years old and over&#xD;
&#xD;
          3. Patient able to give written consent&#xD;
&#xD;
          4. Patient at risk of developing AKI after cardiac surgery (at least one factor)&#xD;
&#xD;
               1. Diabetics (IDDM or NIDDM) with normal kidney function pre-op&#xD;
&#xD;
               2. Patients with eGFR 20-60&#xD;
&#xD;
               3. Patients undergoing combined cardiac procedures when the CPB time is likely to&#xD;
                  exceed 120 minutes&#xD;
&#xD;
               4. Patients with Hb of 12.5 g/dl or below&#xD;
&#xD;
               5. Logistic Euroscore of 5 and above&#xD;
&#xD;
          5. Patient not involved with another study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Emergency surgery&#xD;
&#xD;
          2. Patient unable to give written consent&#xD;
&#xD;
          3. Patient already dialysis dependent or eGFR &lt;20&#xD;
&#xD;
          4. Patient partaking in another study&#xD;
&#xD;
          5. Pregnant patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heyman Luckraz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Wolverhampton NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Royal Wolverhampton NHS Trust</name>
      <address>
        <city>Wolverhampton</city>
        <state>West Midlands</state>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Luckraz H, Giri R, Wrigley B, Nagarajan K, Senanayake E, Sharman E, Beare L, Nevill A. Reduction in acute kidney injury post cardiac surgery using balanced forced diuresis: a randomized, controlled trial. Eur J Cardiothorac Surg. 2021 Apr 13;59(3):562-569. doi: 10.1093/ejcts/ezaa395.</citation>
    <PMID>33236105</PMID>
  </results_reference>
  <results_reference>
    <citation>Luckraz H, Giri R, Wrigley B, Nagarajan K, Senanayake E, Sharman E, Beare L, Nevill A. Balanced forced-diuresis compared to control as a reno-protective approach in cardiac surgery: secondary outcome of a randomized controlled trial, assessment of neutrophil gelatinase-associated lipocalin levels. J Cardiothorac Surg. 2021 Aug 24;16(1):240. doi: 10.1186/s13019-021-01620-w.</citation>
    <PMID>34429137</PMID>
  </results_reference>
  <results_reference>
    <citation>Luckraz H, Giri R, Wrigley B, Nagarajan K, Senanayake E, Sharman E, Beare L, Nevill A. Balanced forced-diuresis as a renal protective approach in cardiac surgery: Secondary outcomes of electrolyte changes. J Card Surg. 2021 Nov;36(11):4125-4131. doi: 10.1111/jocs.15925. Epub 2021 Aug 19.</citation>
    <PMID>34414606</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 23, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

